| |  Online-Ressource |
|---|
| Verfasst von: | Theobald, Vivienne [VerfasserIn]  |
|---|
| | Schmitt, Felix [VerfasserIn] |
|---|
| | Middel, Chiara Simone [VerfasserIn] |
|---|
| | Gaißmaier, Lena [VerfasserIn] |
|---|
| | Brenner, Thorsten [VerfasserIn] |
|---|
| | Weigand, Markus A. [VerfasserIn] |
|---|
| Titel: | Triggering receptor expressed on myeloid cells-1 in sepsis, and current insights into clinical studies |
|---|
| Verf.angabe: | Vivienne Theobald, Felix Carl Fabian Schmitt, Chiara Simone Middel, Lena Gaissmaier, Thorsten Brenner and Markus Alexander Weigand |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | 09 January 2024 |
|---|
| Umfang: | 13 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Published 09 January 2024 ; Gesehen am 14.03.2024 |
|---|
| Titel Quelle: | Enthalten in: Critical care |
|---|
| Ort Quelle: | London : BioMed Central, 1997 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 28(2024), 1, Artikel-ID 17, Seite 1-13 |
|---|
| ISSN Quelle: | 1466-609X |
|---|
| Abstract: | Triggering receptor expressed on myeloid cells-1 (TREM-1) is a pattern recognition receptor and plays a critical role in the immune response. TREM-1 activation leads to the production and release of proinflammatory cytokines, chemokines, as well as its own expression and circulating levels of the cleaved soluble extracellular portion of TREM-1 (sTREM-1). Because patients with sepsis and septic shock show elevated sTREM-1 levels, TREM-1 has attracted attention as an important contributor to the inadequate immune response in this often-deadly condition. Since 2001, when the first blockade of TREM-1 in sepsis was performed, many potential TREM-1 inhibitors have been established in animal models. However, only one of them, nangibotide, has entered clinical trials, which have yielded promising data for future treatment of sepsis, septic shock, and other inflammatory disease such as COVID-19. This review discusses the TREM-1 pathway and important ligands, and highlights the development of novel inhibitors as well as their clinical potential for targeted treatment of various inflammatory conditions. |
|---|
| DOI: | doi:10.1186/s13054-024-04798-2 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1186/s13054-024-04798-2 |
|---|
| | DOI: https://doi.org/10.1186/s13054-024-04798-2 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Biomarkers |
|---|
| | Nangibotide |
|---|
| | Sepsis |
|---|
| | Targeted therapy |
|---|
| | TREM-1 |
|---|
| | TREM-1 inhibition |
|---|
| K10plus-PPN: | 1883470307 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Triggering receptor expressed on myeloid cells-1 in sepsis, and current insights into clinical studies / Theobald, Vivienne [VerfasserIn]; 09 January 2024 (Online-Ressource)
